Enliven Therapeutics ELVN Free cash flow
Free cash flow at other companies
Other financials
Where this comes from
Calculated from Enliven Therapeutics’s reported figures.
The official record: Enliven Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Enliven Therapeutics's free cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Enliven Therapeutics's free cash flow?
- Enliven Therapeutics (ELVN) reported free cash flow of -$19.29M in Q1 2026.
- How has Enliven Therapeutics's free cash flow changed year-over-year?
- Enliven Therapeutics's free cash flow increased by 20.1% year-over-year, from -$24.15M to -$19.29M.
- What is the long-term trend for Enliven Therapeutics's free cash flow?
- Over 4 years (2021 to 2025), Enliven Therapeutics's free cash flow has grown at a 10.8% compound annual growth rate (CAGR), from -$46.78M to -$70.46M.
- What does free cash flow mean?
- Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and maintain or expand its capital asset base. It serves as a critical indicator of a company's ability to fund organic growth, pay down debt, or return capital to shareholders without relying on external financing.